MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study.
Journal
Focus (American Psychiatric Publishing)
ISSN: 1541-4094
Titre abrégé: Focus (Am Psychiatr Publ)
Pays: United States
ID NLM: 101156081
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
pmc-release:
01
07
2024
medline:
5
7
2023
pubmed:
5
7
2023
entrez:
5
7
2023
Statut:
ppublish
Résumé
Post-traumatic stress disorder (PTSD) presents a major public health problem for which currently available treatments are modestly effective. We report the findings of a randomized, double-blind, placebo-controlled, multi-site phase 3 clinical trial (NCT03537014) to test the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for the treatment of patients with severe PTSD, including those with common comorbidities such as dissociation, depression, a history of alcohol and substance use disorders, and childhood trauma. After psychiatric medication washout, participants (
Identifiants
pubmed: 37404971
doi: 10.1176/appi.focus.23021011
pii: FOC_23021011
pmc: PMC10316215
doi:
Types de publication
Journal Article
Langues
eng
Pagination
315-328Informations de copyright
Copyright © 2023 by the American Psychiatric Association.